Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500114877) titled 'A phase III clinical study of Purinostat Mesylate for Injection in patients with diffuse large B-cell lymphoma' on Dec. 18, 2025.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: West China Hospital of Sichuan University/Ruijin Hospital of Shanghai Jiao Tong University School of Medicine
Condition:
Diffuse Large B Cell Lymphoma, DLBCL
Intervention:
Experimental group:Received treatment with purinostat mesylate, with a dosage of 11.2 mg/m^2. Each administration cycle was given intravenously on days 1, 4, 8, and 11, with a 21-day cycle. The total treatment cycle was 6 cycles.
Recruit...